| HOME >> BIOLOGY >> TECHNOLOGY |
Nuevolution partners its technology with pharmaceutical and biotechnology companies, and is also developing an internal pipeline by applying Chemetics(R) to validated cancer and cardiovascular targets. Nuevolution has demonstrated the power of Chemetics(R) by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.
Nuevolution is a privately owned company and has raised EUR 37 million in financing from key Scandinavian investors, including SEB Venture, Sunstone Capital, SLS Venture and Novo A/S.
For more information about Nuevolution A/S, please visit the company's website http://www.nuevolution.com
| SOURCE Nuevolution A/S Copyright©2008 PR Newswire. All rights reserved |